EXCELYA/XENOTHERA
3.5.2021 12:15:09 CEST | Business Wire | Press release
The biotech company XENOTHERA has begun the European clinical trial of its anti-COVID treatment, XAV-19. The Nantes laboratory is the sponsor of the trial, called EUROXAV, which will be carried out by Excelya , a leading European contract research organization (CRO) specializing in clinical research. EUROXAV is a multi-center, double-blind phase III trial that will recruit 722 patients with moderate COVID, hospitalized or monitored remotely. The trial will take place in Greece, Bulgaria, Romania, Spain and Turkey.
The first patient in the trial was recruited on April 28th at Professor Poulakou's center (GR04) in Greece. The cohort of 722 patients will complement the 398 patients in the POLYCOR trial, a trial carried out in 35 French hospitals under the sponsorship of the Nantes University Hospital, which has just closed its recruitment phase with results expected Summer 2021.
"Excelya is very proud to support XENOTHERA in the development of XAV19, which holds great promise in the battle against COVID19. After taking several months to develop the EUROXAV project, the inclusion of this first patient represents an important milestone. We hope to work quickly to make results available and initiate the next steps to benefit patients and caregivers," said Alan Morgan, CEO of Excelya .
“This milestone marks the start of the EUROXAV trial, the results of which are awaited with great interest. The aim of the trial is to evaluate the efficacy of XAV-19 in hospitalized and ambulatory patients, which will allow us to analyze the medical value of XAV-19 in clinical situations where there is currently no satisfactory therapeutic solution.” comments Odile Duvaux, co-founder and president of XENOTHERA.
*********************
About XAV-19:
XENOTHERA's drug candidate XAV-19 is a protective anti-SARS-CoV-2 polyclonal antibody similar to the natural human response
. Based on a unique and patented proprietary technology, it acts through several mechanisms of action, including neutralizing the virus, reducing inflammation and limiting the risk of cytokine storms.
About XENOTHERA:
Founded in 2014, XENOTHERA is a Nantes-based biotech company that develops "glyco-humanized" polyclonal antibodies. Its technological platform is built on a dual expertise in genetics and immunology. The company has a complete portfolio of products, the first of which, LIS1, an immunosuppressant in transplantation, has been in the clinic since 2019. XENOTHERA has also been developing its treatment for coronavirus infections for several years. XAV-19 is XENOTHERA's treatment for patients at the beginning of hospitalization, it is based on a unique patented antibody production technology, developed and proven for several years by the biotech.
XENOTHERA, a member of the Atlanpole Biotherapies competitiveness cluster, is part of the scientific and medical environment of the Pays de la Loire. The company has been supported since its creation by private investors, by the Pays de la Loire Region and by BPI France. Since its creation, the company has raised more than 23 million euros to finance all of its products.
For more information: www.xenothera.com
Follow XENOTHERA on social networks: LinkedIn
Twitter
About Excelya Group:
Excelya is an independent European contract research organization with over 800 employees, 17 offices and 12 legal entities spread throughout Europe. Excelya offers all cooperation models, from consulting to functional service providing to full-service. It provides these research services across multiple industries, including pharmaceutical, biotech, medical devices, cosmetics and nutrition. As a fully integrated CRO, Excelya undertakes the design and execution of Phase I clinical trials to post-marketing studies, safety, biometrics and market access projects. Excelya is committed to providing preeminent experts who work hand-in-hand with its clients to accelerate end-to-end drug development, leverage data science and reimagine patient care.
For more information, please visit excelya.com
.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210503005365/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
IFF to Webcast Fireside Chat at Barclays Global Consumer Conference on Sept. 1018.8.2026 22:15:00 CEST | Press release
IFF (NYSE: IFF) today announced that Chief Executive Officer Erik Fyrwald will participate in a fireside chat at the Barclays Global Consumer Conference on Thursday, Sept. 10, 2026 at 945 a.m. ET. Investors may access the live webcast on the Company's website at ir.iff.com. For those unable to listen to the live webcast, a recorded version will be made available for replay. Welcome to IFF At IFF (NYSE: IFF), we make joy through science, creativity and heart. As the global leader in flavors, fragrances, and health and biosciences, we deliver groundbreaking, sustainable innovations that elevate everyday products—advancing wellness, delighting the senses and enhancing the human experience.Learn more at iff.com, LinkedIn, Instagram and Facebook. View source version on businesswire.com: https://www.businesswire.com/news/home/20260818490253/en/
Lehman Brothers Treasury Announces the Successful Sale of its Remaining Intercompany Claim against Lehman Brothers Holdings Inc.18.8.2026 21:15:00 CEST | Press release
In connection with its previously announced final wind-down, Lehman Brothers Treasury Co. B.V. in liquidation (“LBT”), through its U.S. counsel Herbert Smith Freehills Kramer (US) LLP, announced that its placement agent, Seaport Loan Products LLC, successfully closed the sale of LBT’s remaining $19.6 billion Class 4A intercompany claim against Lehman Brothers Holdings Inc. The net proceeds of the sale, together with certain available cash (but after deducting various sale-related and other administrative costs and expenses), will be used to fund a final distribution to the holders of LBT’s existing notes, after which such existing notes will be canceled and LBT shall be fully wound down. As a result, LBT will cease to exist. LBT expects the final distribution to occur in the course of October 2026 and the wind down to have been completed before the end of 2026. View source version on businesswire.com: https://www.businesswire.com/news/home/20260818004215/en/
GenBio AI Builds First World Model of the Human Cell18.8.2026 15:00:00 CEST | Press release
First-of-its-kind system simulates human cell behavior across the full biological hierarchy, from DNA and RNA through protein to the whole-cell level GenBio AI ('GenBio') is an AI for Science company co-founded by Nobel Laureate David Baker, leading AI scientist Eric Xing, and other prominent life science and artificial intelligence researchers from Stanford, Carnegie Mellon University, Mohamed Bin Zayed University of Artificial Intelligence, Harvard, Weizmann Institute, and other research institutions. Today, the company introduced AIDO Cell, its virtual cell world model — the first system capable of simulating a human cell, both in its natural state and in response to drugs and other interventions, across its full biological hierarchy, from DNA and RNA through protein to the whole-cell level. A Key First in Biological and Medical Sciences: Full-hierarchy virtual cell simulation has been widely identified as a key milestone in computational biology. Compared to the previous efforts by
Xsolla Partner Network Expands Verified Creator Partnerships and Unifies Campaign Management Ahead of gamescom 202618.8.2026 15:00:00 CEST | Press release
Developers Gain Vetted Creator Partnerships And A Single Campaign Workflow, Managed From The Publisher Account They Already Use Xsolla, a global video game commerce company, today announced an expansion of the Xsolla Partner Network ahead of gamescom 2026 in Cologne, giving game developers a simpler, more reliable way to grow their games through creators. The creator platform now lives within Xsolla Publisher Account, where developers already run their business, with verified creator onboarding and a redesigned and unified campaign workflow. Flat-fee campaigns, a new guaranteed payment option alongside revenue share, and data-driven creator recommendations are coming soon. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260818140062/en/ Graphic: Xsolla Xsolla Partner Network gives developers one place to launch, manage, track, and report on creator campaigns while Xsolla handles payments, payouts, taxes, and compliance.Verifi
KOCCA to Showcase 13 Korean Game Companies at ‘Gamescom 2026’ with PC, Mobile, and VR Lineups18.8.2026 14:48:00 CEST | Press release
- Featuring a diverse lineup of roguelike deckbuilders, AI-powered rhythm education, and cooperative horror games - Ranging from new titles based on the popular animated IP ‘LARVA’ to real-time K-POP dance coaching content - Hands-on experience available August 26–28 at the Korea Joint Pavilion B2B Hall, Koelnmesse, Booth Hall 3.2 C-050g–D051g The Korea Creative Content Agency (KOCCA) announced that 13 Korean game companies will gather under one roof at Gamescom 2026, Europe’s largest game show, held in Cologne, Germany, from August 26 to 28 (B2B, 09:00~20:00). Located in Booth Hall 3.2 C-050g–D051g, the Korea Joint Pavilion offers visitors hands-on experiences with an expansive lineup of titles, ranging from PC and mobile games to VR-powered titles across diverse genres. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260818271881/en/ KOCCA will bring 13 Korean game companies to Gamescom 2026 in Cologne, Germany (Image: KOCC
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom